Publications by authors named "Jonathan Dry"

Claim this Profile
L
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R Dry

Cancer Cell· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R Dry

Cancer Cell· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.
Orsolya Papp, Viktória Jordán, Szabolcs Hetey, Róbert Balázs, Valér Kaszás, Jonathan R Dry

NPJ Syst Biol Appl· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, Marcin Skrzypski, Alexander M Frankell, Jonathan R Dry

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.
Orsolya Papp, Viktória Jordán, Szabolcs Hetey, Róbert Balázs, Valér Kaszás, Jonathan R Dry

NPJ Syst Biol Appl· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study.
Kyle M Hernandez, Kelli S Bramlett, Phaedra Agius, Jonathan Baden, Ru Cao, Jonathan R Dry

J Mol Diagn· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Steven W Criscione, Matthew J Martin, Derek B Oien, Aparna Gorthi, Ricardo J Miragaia, Jonathan R Dry

NPJ Precis Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Privacy preserving validation for multiomic prediction models.
Talal Ahmed, Mark A Carty, Stephane Wenric, Jonathan R Dry, Ameen A Salahudeen

Brief Bioinform· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Benjamin D Leibowitz, Bonnie V Dougherty, Joshua S K Bell, Joshuah Kapilivsky, Jackson Michuda, Jonathan R Dry

BMC Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.
Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, Michaël Ughetto, Jonathan R Dry

Nat Commun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
Zhongwu Lai, Matthew Brosnan, Ethan S Sokol, Mingchao Xie, Jonathan R Dry

BMC Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pan-cancer organoid platform for precision medicine.
Brian M Larsen, Madhavi Kannan, Lee F Langer, Benjamin D Leibowitz, Aicha Bentaieb, Jonathan R Dry

Cell Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BloodPAC Data Commons for Liquid Biopsy Data.
Robert L Grossman, Jonathan R Dry, Sean E Hanlon, Donald J Johann, Anand Kolatkar

JCO Clin Cancer Inform· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy.
Chao Fang, Dong Xu, Jing Su, Jonathan R Dry, Bolan Linghu

NPJ Digit Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates.
Dennis Wang, James Hensman, Ginte Kutkaite, Tzen S Toh, Ana Galhoz, Jonathan R Dry

Elife· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens.
Iñigo Ayestaran, Ana Galhoz, Elmar Spiegel, Ben Sidders, Jonathan R Dry

Patterns (N Y)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stratification and prediction of drug synergy based on target functional similarity.
Mi Yang, Patricia Jaaks, Jonathan Dry, Mathew Garnett, Michael P Menden

NPJ Syst Biol Appl· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O'Connor, Deanna L Russell, Jonathan R Dry

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Matthew J Sale, Emma Minihane, Noel R Monks, Rebecca Gilley, Frances M Richards, Jonathan R Dry

Nat Commun· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Michael P Menden, Dennis Wang, Mike J Mason, Bence Szalai, Krishna C Bulusu, Jonathan R Dry

Nat Commun· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF amplification whereas KRAS amplification promotes EMT-chemoresistance.
Matthew J Sale, Kathryn Balmanno, Jayeta Saxena, Eiko Ozono, Katarzyna Wojdyla, Jonathan R Dry

Nat Commun· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in -mutant mammary tumours.
Liliana D Ordonez, Trevor Hay, Robert McEwen, Urszula M Polanska, Adina Hughes, Jonathan Dry

Oncotarget· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Zebin Wang, Shaun E Grosskurth, Tony Cheung, Philip Petteruti, Jingwen Zhang, Jonathan R Dry

Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer.
Soomin Ahn, Roz Brant, Alan Sharpe, Jonathan R Dry, Darren R Hodgson

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of primary relapse/refractory DLBCL identifies shifts in mutation spectrum.
Danielle M Greenawalt, Winnie S Liang, Sakina Saif, Justin Johnson, Petar Todorov, Jonathan R Dry

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis